Skip to main content
. Author manuscript; available in PMC: 2014 Dec 1.
Published in final edited form as: Arthritis Rheum. 2013 Dec;65(12):3176–3185. doi: 10.1002/art.38174

Figure 4.

Figure 4

Effects of P2X7 small interfering RNA (siRNA) treatment on lupus syndrome in MRL/lpr mice. MRL/lpr mice, age 14 weeks, were treated with either control siRNA or P2X7 siRNA for 10 days. A, The kidneys were analyzed by Western blotting (representative bands shown) (left) for relative protein expression of P2X7, NLRP3, ASC, and caspase l-p20, and the results, normalized to the values for GAPDH, were quantified and expressed as the mean ± SD (n = 6 per group) (right). B–E, Serum anti–double-stranded DNA (anti-dsDNA) antibody levels (determined by enzyme-linked immunosorbent assay [ELISA]) (B), the Thl7:Treg cell ratio in the spleens (C), serum interleukin-1β (IL-1β) levels (determined by ELISA) (D), and serum IL-17 levels (determined by ELISA) (E) were compared between the 2 groups. Bars show the mean ± SD (n = 6 per group). * = P < 0.01; ** = P < 0.05 versus control siRNA-treated mice.